Branded drug prices leapt almost 15% last year, led by pain pills, COPD and heart meds

Carly Helfand

It's no secret that drugmakers often rely on price hikes to keep U.S. sales growth coming, especially on older whose patents are close to the ends of their lives. But according to new data, spiked more than 10% last –a trend that may fuel the payer backlash that's been steadily mounting.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS